ZA964778B - Methods for minimizing bone loss. - Google Patents

Methods for minimizing bone loss.

Info

Publication number
ZA964778B
ZA964778B ZA9604778A ZA964778A ZA964778B ZA 964778 B ZA964778 B ZA 964778B ZA 9604778 A ZA9604778 A ZA 9604778A ZA 964778 A ZA964778 A ZA 964778A ZA 964778 B ZA964778 B ZA 964778B
Authority
ZA
South Africa
Prior art keywords
methods
bone loss
minimizing bone
minimizing
loss
Prior art date
Application number
ZA9604778A
Other languages
English (en)
Inventor
George Joseph Cullinan
Steven Anthony Fontana
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ZA964778B publication Critical patent/ZA964778B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Glass Compositions (AREA)
  • Control Of Motors That Do Not Use Commutators (AREA)
  • Surface Acoustic Wave Elements And Circuit Networks Thereof (AREA)
ZA9604778A 1995-06-06 1996-06-06 Methods for minimizing bone loss. ZA964778B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/467,475 US5599822A (en) 1995-06-06 1995-06-06 Methods for minimizing bone loss

Publications (1)

Publication Number Publication Date
ZA964778B true ZA964778B (en) 1997-12-08

Family

ID=23855853

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9604778A ZA964778B (en) 1995-06-06 1996-06-06 Methods for minimizing bone loss.

Country Status (22)

Country Link
US (1) US5599822A (fr)
EP (1) EP0747054B1 (fr)
JP (1) JPH11507051A (fr)
KR (1) KR19990022498A (fr)
CN (1) CN1192145A (fr)
AU (1) AU696209B2 (fr)
BR (1) BR9608389A (fr)
CA (1) CA2223055A1 (fr)
CO (1) CO4700446A1 (fr)
CZ (1) CZ382997A3 (fr)
DE (1) DE69623074T2 (fr)
EA (1) EA000763B1 (fr)
ES (1) ES2181849T3 (fr)
HU (1) HUP9900849A3 (fr)
IL (1) IL118590A (fr)
NO (1) NO975581D0 (fr)
PL (1) PL323935A1 (fr)
TR (1) TR199701507T1 (fr)
TW (1) TW372969B (fr)
WO (1) WO1996039138A1 (fr)
YU (1) YU34396A (fr)
ZA (1) ZA964778B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702401D0 (sv) * 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
US6096764A (en) * 1997-08-21 2000-08-01 Eli Lilly And Company Methods for inhibiting detrimental side-effects due to GnRH of GnRH agonist administration
DE19825591A1 (de) * 1998-06-09 1999-12-23 Jenapharm Gmbh Pharmazeutische Kombinationen zum Ausgleich eines Testosteron-Defizits beim Mann mit gleichzeitigem Schutz der Prostata
AU7993500A (en) * 1999-11-15 2001-05-30 New Millennium Pharmaceutical Research, Inc. Intranasal administration of raloxifene and tamoxifen
EP1113007A1 (fr) 1999-12-24 2001-07-04 Pfizer Inc. Composés de tétrahydroisoquinoline comme agonistes/antagonistes d'oestrogène
US20050124537A1 (en) * 2000-04-27 2005-06-09 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US6756480B2 (en) * 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
EP1180364A1 (fr) * 2000-08-15 2002-02-20 Octagene GmbH Hormones stéroidiennes comme agents de transfert
CA2490580C (fr) 2002-07-22 2012-12-11 Eli Lilly And Company Modulateurs selectifs des recepteurs oestrogeniques contenant un groupe naphtalene
JP2007537274A (ja) 2004-05-10 2007-12-20 ナステック ファーマスーティカル カンパニー インク． 副甲状腺ホルモンの粘膜送達を増強するための組成物及び方法
BRPI0509788A (pt) 2004-05-13 2007-10-23 Alza Corp aparato e método para liberação transdérmica de agentes de hormÈnio paratireóides
WO2007044375A2 (fr) * 2005-10-06 2007-04-19 Nastech Pharmaceutical Company Inc. Formulations pth et procédés d'utilisation
WO2007044069A2 (fr) * 2005-10-06 2007-04-19 Nastech Pharmaceutical Company Inc. Formulations de pth et procedes d'utilisation
EP4098264A1 (fr) * 2017-06-01 2022-12-07 Nexyon Biotech Co., Ltd. Composition pharmaceutique pour la prévention ou le traitement d'une maladie osseuse
CN108785264A (zh) * 2018-07-03 2018-11-13 威海贯标信息科技有限公司 一种达那唑片剂组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3135743A (en) * 1960-06-29 1964-06-02 Sterling Drug Inc Steroido[2. 3-d]isoxazoles and preparation thereof
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss

Also Published As

Publication number Publication date
IL118590A (en) 1999-10-28
KR19990022498A (ko) 1999-03-25
HUP9900849A2 (hu) 1999-09-28
DE69623074D1 (de) 2002-09-26
US5599822A (en) 1997-02-04
CN1192145A (zh) 1998-09-02
IL118590A0 (en) 1996-10-16
CA2223055A1 (fr) 1996-12-12
HUP9900849A3 (en) 1999-11-29
TW372969B (en) 1999-11-01
BR9608389A (pt) 1999-05-04
DE69623074T2 (de) 2003-05-08
WO1996039138A1 (fr) 1996-12-12
EP0747054B1 (fr) 2002-08-21
EP0747054A3 (fr) 1997-03-05
EA000763B1 (ru) 2000-04-24
EP0747054A2 (fr) 1996-12-11
NO975581L (no) 1997-12-03
ES2181849T3 (es) 2003-03-01
AU696209B2 (en) 1998-09-03
CZ382997A3 (cs) 1998-09-16
PL323935A1 (en) 1998-04-27
NO975581D0 (no) 1997-12-03
JPH11507051A (ja) 1999-06-22
CO4700446A1 (es) 1998-12-29
EA199800013A1 (ru) 1998-06-25
TR199701507T1 (xx) 1998-02-21
YU34396A (sh) 1999-07-28
AU6043096A (en) 1996-12-24

Similar Documents

Publication Publication Date Title
ZA963694B (en) Methods for inhibiting bone loss.
PH31315A (en) Methods for inhibiting bone loss using substitutedbenzothiophene.
ZA967315B (en) Biphenylamides.
MX213417B (es) Fenilpiridazinonas.
ZA964468B (en) Triazolylmethyl-cyclopentanols.
ZA961955B (en) Indazolecarboxamides.
ZA964778B (en) Methods for minimizing bone loss.
DE69610844D1 (en) Hydroformylierungsverfahren.
AU5743396A (en) Methods for inhibiting bone loss
ZA969625B (en) 25-Hydroxy-16-ene-26, 27-bishomo-cholecalciferols
ZA966399B (en) Endothelin-receptor-antagonists.
AU5743696A (en) Methods for inhibiting bone loss
ZA964681B (en) Methods for minimizing bone loss.
ZA9710349B (en) Process for making benzisothiazolin-3-ones.
ZA966933B (en) Endothelin-receptor-antagonists.
ZA966750B (en) Halogenobenzimidazoles.
ZA9610053B (en) Process for preparing dioxoazabicyclohexanes.
ZA9610458B (en) Novel method.
ZA967314B (en) Carbamoylcarboxamides.
ZA971775B (en) Novel method.
ZA969560B (en) Substituted 1-methyl-3-phenylpyrazoles.
ZA968953B (en) 24-homo-26,27-hexafluoro-cholecalciferols
HK1016577A1 (en) 25-hydroxy-16-ene-26,27-bishomo-cholecalciferols
SI0874814T1 (en) 25-hydroxy-16-ene-26,27-bishomo-cholecalciferols
ZA966114B (en) Scatterpile pusher.